End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease

Arun J. Sanyal, Brent A. Neuschwander-Tetri, James Tonascia

Research output: Contribution to journal › Editorial › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease'. Together they form a unique fingerprint.